8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 13, 2026·SEC
Material company update
Mar 17, 2026·SEC
ClearPoint Neuro, Inc.(CLPT)Earnings, Financials & Key Ratios
CLPT•NASDAQ
Price updated Jun 19, 2026
AboutClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.Show more
- Revenue$37M+17.8%
- EBITDA-$22M-22.9%
- Net Income-$26M-35.0%
- EPS (Diluted)-0.90-28.6%
- Gross Margin61.38%+0.8%
- EBITDA Margin-59.31%-4.3%
- Operating Margin-65.36%-3.9%
- Net Margin-69.08%-14.6%
- ROE-95.64%-17.7%
CLPT Key Insights
ClearPoint Neuro, Inc. (CLPT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 86 (top 14%)
- ✓Strong 5Y sales CAGR of 23.6%
✗Weaknesses
- ✗High debt to equity ratio of 2.1x
- ✗Profits declining 30.4% over 5 years
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 18.0x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CLPT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CLPT Price & Volume
ClearPoint Neuro, Inc. (CLPT) stock price & volume — 10-year historical chart
Loading chart...
CLPT Growth Metrics
ClearPoint Neuro, Inc. (CLPT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years23.19%
5 Years23.58%
3 Years21.62%
TTM25.99%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-39.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-32.89%
Return on Capital
10 Years-69.83%
5 Years-43.47%
3 Years-52.28%
Last Year-41.73%
CLPT Recent Earnings
ClearPoint Neuro, Inc. (CLPT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.32-14.3%
$0.28
Rev
$12M+1.3%
$12M
Q2 2026
Mar 17, 2026Metric
Actual
Est
EPS
$0.27-22.7%
$0.22
Rev
$10M+3.5%
$10M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.21-5.0%
$0.20
Rev
$9M-14.8%
$10M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.21-5.0%
$0.20
Rev
$9M-6.0%
$10M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.32vs $0.28-14.3% | $12Mvs $12M+1.3% |
| Q2 2026 | Mar 17, 2026 | $0.27vs $0.22-22.7% | $10Mvs $10M+3.5% |
| Q4 2025 | Nov 6, 2025 | $0.21vs $0.20-5.0% | $9Mvs $10M-14.8% |
| Q3 2025 | Aug 12, 2025 | $0.21vs $0.20-5.0% | $9Mvs $10M-6.0% |
Based on last 12 quarters of dataView full earnings history →
CLPT Peer Comparison
ClearPoint Neuro, Inc. (CLPT) competitors in Neuromodulation and neuro devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 ABT | 153.68B | 88.38 | 11.57 | 4.59% | 31.88% | 27.26% | 0.32 | |
 MDT | 101.86B | 79.34 | 21.98 | 3.62% | 13% | 9.49% | 0.59 | |
 ANGO | 505.13M | 12.15 | -14.64 | -3.76% | -9.02% | -15.71% | ||
 ATEC | 1.33B | 8.81 | -9.18 | 24.95% | -21.07% | -443.09% | 17.21 | |
 GE | 373.67B | 357.64 | 43.83 | 18.48% | 17.91% | 45.85% | 1.08 | |
 GEHC | 28.02B | 61.59 | 13.54 | 4.84% | 7.54% | 14.45% | 0.94 |
Compare CLPT vs Peers
ClearPoint Neuro, Inc. (CLPT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CLPT Income Statement
ClearPoint Neuro, Inc. (CLPT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 7.38M | 7.35M | 11.22M | 12.83M | 16.3M | 20.55M | 23.95M | 31.39M | 36.97M | 40.61M |
Revenue Growth % | 28.35% | -0.36% | 52.54% | 14.37% | 27.05% | 26.09% | 16.56% | 31.04% | 17.78% | 25.99% |
Cost of Goods Sold | 2.9M | 2.43M | 3.94M | 3.71M | 5.18M | 7.02M | 10.34M | 12.27M | 14.28M | 15.51M |
COGS % of Revenue | 39.28% | 33.09% | 35.14% | 28.91% | 31.76% | 34.16% | 43.17% | 39.08% | 38.62% | - |
Gross Profit | 4.48M▲ 0% | 4.92M▲ 9.8% | 7.28M▲ 47.9% | 9.12M▲ 25.4% | 11.12M▲ 22.0% | 13.53M▲ 21.6% | 13.61M▲ 0.6% | 19.12M▲ 40.5% | 22.69M▲ 18.7% | 25.11M▲ 0% |
Gross Margin % | 60.72% | 66.91% | 64.86% | 71.09% | 68.24% | 65.84% | 56.83% | 60.92% | 61.38% | 61.82% |
Gross Profit Growth % | 44.23% | 9.81% | 47.86% | 25.36% | 21.96% | 21.65% | 0.61% | 40.46% | 18.67% | - |
Operating Expenses | 10.82M | 10.17M | 11.87M | 15.34M | 24.5M | 29.86M | 36.06M | 38.87M | 46.86M | 51.59M |
OpEx % of Revenue | 146.58% | 138.28% | 105.81% | 119.57% | 150.3% | 145.31% | 150.53% | 123.82% | 126.74% | - |
Selling, General & Admin | 8M | 7.86M | 9.06M | 10.65M | 15.22M | 18.97M | 24.35M | 26.48M | 32.96M | 36.76M |
SG&A % of Revenue | 108.45% | 106.86% | 80.76% | 83.05% | 93.36% | 92.3% | 101.65% | 84.35% | 89.15% | - |
Research & Development | 2.81M | 2.31M | 2.81M | 4.69M | 9.28M | 10.89M | 11.71M | 12.39M | 13.9M | 15.04M |
R&D % of Revenue | 38.13% | 31.42% | 25.05% | 36.53% | 56.94% | 53.01% | 48.88% | 39.48% | 37.59% | - |
Other Operating Expenses | 16.68K | 364 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -207K |
Operating Income | -6.34M▲ 0% | -5.25M▲ 17.2% | -4.59M▲ 12.5% | -6.22M▼ 35.4% | -13.37M▼ 115.0% | -16.33M▼ 22.1% | -22.45M▼ 37.4% | -19.75M▲ 12.0% | -24.16M▼ 22.4% | -26.48M▲ 0% |
Operating Margin % | -85.86% | -71.37% | -40.96% | -48.48% | -82.05% | -79.47% | -93.7% | -62.91% | -65.36% | -65.2% |
Operating Income Growth % | 15.4% | 17.17% | 12.46% | -35.39% | -115.02% | -22.12% | -37.44% | 12.03% | -22.37% | - |
EBITDA | -6.22M | -5.14M | -4.34M | -5.67M | -12.68M | -15.55M | -20.99M | -17.84M | -21.93M | -23.82M |
EBITDA Margin % | -84.28% | -69.88% | -38.72% | -44.2% | -77.81% | -75.69% | -87.62% | -56.84% | -59.31% | -58.66% |
EBITDA Growth % | 15.19% | 17.38% | 15.48% | -30.55% | -123.67% | -22.65% | -34.93% | 14.99% | -22.89% | -19.62% |
D&A (Non-Cash Add-back) | 116.45K | 109.44K | 251K | 550K | 692K | 777K | 1.46M | 1.9M | 2.24M | 2.66M |
EBIT | -6.29M | -5.18M | -4.58M | -5.34M | -13.44M | -16.35M | -22.45M | -19.75M | -24.16M | -26.59M |
Net Interest Income | -872.93K | -980.38K | -955K | -1.44M | -973K | -81K | 386K | 872K | -1.18M | -2.36M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 386K | 872K | 1.21M | 351K |
Interest Expense | 872.93K | 980.38K | 955K | 1.44M | 973K | 81K | 0 | 0 | 2.39M | 2.71M |
Other Income/Expense | -831.52K | -915.7K | -946K | -562K | -1.04M | -103K | 357K | 832K | -1.32M | -2.54M |
Pretax Income | -7.17M▲ 0% | -6.16M▲ 14.0% | -5.54M▲ 10.1% | -6.78M▼ 22.4% | -14.41M▼ 112.5% | -16.43M▼ 14.1% | -22.09M▼ 34.4% | -18.91M▲ 14.4% | -25.48M▼ 34.7% | -29.02M▲ 0% |
Pretax Margin % | -97.12% | -83.82% | -49.39% | -52.86% | -88.41% | -79.97% | -92.21% | -60.25% | -68.93% | -71.46% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 55K | 45K |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0.22% | -0.16% |
Net Income | -7.17M▲ 0% | -6.16M▲ 14.0% | -5.54M▲ 10.1% | -6.78M▼ 22.4% | -14.41M▼ 112.5% | -16.43M▼ 14.1% | -22.09M▼ 34.4% | -18.91M▲ 14.4% | -25.54M▼ 35.0% | -29.07M▲ 0% |
Net Margin % | -97.12% | -83.82% | -49.39% | -52.86% | -88.41% | -79.97% | -92.21% | -60.25% | -69.08% | -71.57% |
Net Income Growth % | 11.18% | 14.01% | 10.12% | -22.42% | -112.47% | -14.05% | -34.4% | 14.37% | -35.03% | -39.78% |
Net Income (Continuing) | -7.17M | -6.16M | -5.54M | -6.78M | -14.41M | -16.43M | -22.09M | -18.91M | -25.54M | -29.07M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.93▲ 0% | -0.56▲ 39.8% | -0.49▲ 12.5% | -0.43▲ 12.2% | -0.69▼ 60.5% | -0.68▲ 1.4% | -0.90▼ 32.4% | -0.70▲ 22.2% | -0.90▼ 28.6% | -0.98▲ 0% |
EPS Growth % | 68.26% | 39.78% | 12.5% | 12.24% | -60.47% | 1.45% | -32.35% | 22.22% | -28.57% | -32.89% |
EPS (Basic) | -0.93 | -0.56 | -0.49 | -0.43 | -0.69 | -0.68 | -0.90 | -0.70 | -0.90 | - |
Diluted Shares Outstanding | 7.74M | 10.93M | 13.16M | 15.85M | 20.73M | 24.18M | 24.61M | 27.03M | 28.32M | 29.55M |
Basic Shares Outstanding | 7.74M | 10.93M | 13.16M | 15.85M | 20.73M | 24.18M | 24.61M | 27.03M | 28.32M | 29.55M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CLPT Balance Sheet
ClearPoint Neuro, Inc. (CLPT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 12.75M | 6.65M | 10.38M | 25.46M | 61.89M | 51.18M | 36.17M | 33.36M | 63.6M | 54.88M |
Cash & Short-Term Investments | 9.29M | 3.1M | 5.7M | 20.1M | 54.11M | 37.49M | 23.14M | 20.1M | 45.92M | 35.59M |
Cash Only | 9.29M | 3.1M | 5.7M | 20.1M | 54.11M | 27.61M | 23.14M | 20.1M | 45.92M | 35.59M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 9.87M | 0 | 0 | 0 | 0 |
Accounts Receivable | 949.41K | 1.23M | 1.09M | 1.88M | 2.34M | 2.67M | 3.94M | 4.71M | 7.26M | 8.66M |
Days Sales Outstanding | 46.96 | 61.25 | 35.47 | 53.52 | 52.33 | 47.33 | 60.09 | 54.8 | 71.7 | 54.34 |
Inventory | 2.31M | 2.11M | 3.24M | 3.24M | 4.94M | 9.3M | 7.91M | 6.86M | 8.36M | 8.57M |
Days Inventory Outstanding | 291.39 | 315.93 | 300 | 318.65 | 348.22 | 483.7 | 279.23 | 204.19 | 213.67 | 175.43 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 1.72M | 0 | 1.68M | 2.06M | 2.05M |
Total Non-Current Assets | 1.15M | 1.2M | 1.54M | 4.06M | 3.69M | 4.31M | 6.49M | 5.83M | 34.15M | 38.54M |
Property, Plant & Equipment | 267.67K | 377.71K | 821K | 3.06M | 2.78M | 2.7M | 4.95M | 5.09M | 11.05M | 16M |
Fixed Asset Turnover | 27.57x | 19.47x | 13.66x | 4.20x | 5.86x | 7.61x | 4.84x | 6.17x | 3.35x | 3.75x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.47M | 7.47M |
Intangible Assets | 0 | 0 | 0 | 353K | 265K | 1.03M | 1.04M | 484K | 13.92M | 13.42M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 883.54K | 824.44K | 722K | 648K | 644K | 581K | 495K | 251K | 1.7M | 1.65M |
Total Assets | 13.9M▲ 0% | 7.86M▼ 43.5% | 11.93M▲ 51.8% | 29.52M▲ 147.5% | 65.58M▲ 122.2% | 55.49M▼ 15.4% | 42.66M▼ 23.1% | 39.19M▼ 8.1% | 97.75M▲ 149.4% | 93.42M▲ 0% |
Asset Turnover | 0.53x | 0.94x | 0.94x | 0.43x | 0.25x | 0.37x | 0.56x | 0.80x | 0.38x | 0.52x |
Asset Growth % | 87.78% | -43.47% | 51.8% | 147.49% | 122.17% | -15.39% | -23.12% | -8.14% | 149.42% | 429.84% |
Total Current Liabilities | 4.4M | 2.01M | 3.83M | 3.2M | 4.75M | 6.79M | 7.43M | 10.35M | 10.77M | 9.48M |
Accounts Payable | 759.45K | 500.93K | 966K | 300K | 427K | 272K | 393K | 1.34M | 1.26M | 2.33M |
Days Payables Outstanding | 95.62 | 75.15 | 89.44 | 29.52 | 30.11 | 14.14 | 13.87 | 39.87 | 32.11 | 34.37 |
Short-Term Debt | 2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 694K | 234K |
Deferred Revenue (Current) | 256.18K | 350.96K | 1.02M | 562K | 678K | 1.07M | 2.61M | 2.12M | 0 | 3.1M |
Other Current Liabilities | 575.95K | 741.8K | 1.41M | 1.59M | 2.6M | 2.82M | 2.95M | 4.88M | 8.81M | 6.92M |
Current Ratio | 2.90x | 3.31x | 2.71x | 7.96x | 13.02x | 7.54x | 4.87x | 3.22x | 5.91x | 5.79x |
Quick Ratio | 2.37x | 2.27x | 1.86x | 6.95x | 11.98x | 6.17x | 3.80x | 2.56x | 5.13x | 4.88x |
Cash Conversion Cycle | 242.72 | 302.03 | 246.02 | 342.64 | 370.44 | 516.89 | 325.45 | 219.12 | 253.27 | 195.39 |
Total Non-Current Liabilities | 3.67M | 4.34M | 3.51M | 23.94M | 12.04M | 11.81M | 14.06M | 3.45M | 58.96M | 65.09M |
Long-Term Debt | 2.92M | 3.48M | 2.07M | 21.28M | 9.84M | 9.89M | 9.95M | 0 | 49.08M | 49.64M |
Capital Lease Obligations | 0 | 0 | 277K | 2.45M | 1.94M | 1.53M | 3.57M | 3.01M | 8.46M | 34.65M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 354K | 708K |
Other Non-Current Liabilities | 752.5K | 997.7K | 960K | 0 | 0 | 0 | 0 | 0 | 489K | 779K |
Total Liabilities | 8.07M | 6.35M | 7.34M | 27.14M | 16.79M | 18.6M | 21.49M | 13.8M | 69.73M | 74.58M |
Total Debt | 4.92M | 3.48M | 2.46M | 24.12M | 12.28M | 11.99M | 13.94M | 3.57M | 58.23M | 63.59M |
Net Debt | -4.37M | 379.51K | -3.23M | 4.02M | -41.83M | -15.63M | -9.2M | -16.54M | 12.31M | 28M |
Debt / Equity | 0.84x | 2.30x | 0.54x | 10.15x | 0.25x | 0.32x | 0.66x | 0.14x | 2.08x | 3.37x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -2.67x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.18x |
Interest Coverage | -7.21x | -5.29x | -4.80x | -3.70x | -13.81x | -201.90x | - | - | -10.12x | -9.82x |
Total Equity | 5.83M▲ 0% | 1.51M▼ 74.1% | 4.59M▲ 203.5% | 2.38M▼ 48.2% | 48.79M▲ 1952.5% | 36.89M▼ 24.4% | 21.17M▼ 42.6% | 25.39M▲ 19.9% | 28.02M▲ 10.4% | 18.84M▲ 0% |
Equity Growth % | 870.93% | -74.08% | 203.51% | -48.17% | 1952.46% | -24.39% | -42.6% | 19.91% | 10.36% | -79.19% |
Book Value per Share | 0.75 | 0.14 | 0.35 | 0.15 | 2.35 | 1.53 | 0.86 | 0.94 | 0.99 | 0.64 |
Total Shareholders' Equity | 5.83M | 1.51M | 4.59M | 2.38M | 48.79M | 36.89M | 21.17M | 25.39M | 28.02M | 18.84M |
Common Stock | 106.94K | 110.18K | 152K | 170K | 237K | 246K | 247K | 276K | 294K | 300K |
Retained Earnings | -101.04M | -107.2M | -112.74M | -119.52M | -133.93M | -150.37M | -172.46M | -191.37M | -216.91M | -226.46M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -1.67M | -1.72M | 0 | 0 | 0 | 0 | 0 | 0 | 5.64M | 5.54M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CLPT Cash Flow Statement
ClearPoint Neuro, Inc. (CLPT) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -5.99M | -4.63M | -2.85M | -7.81M | -12.7M | -16.17M | -13.72M | -8.95M | -23.93M | -25.72M |
Operating CF Margin % | -81.2% | -62.97% | -25.4% | -60.86% | -77.9% | -78.67% | -57.27% | -28.51% | -64.71% | - |
Operating CF Growth % | -2.96% | 22.73% | 38.46% | -174.01% | -62.62% | -27.33% | 15.14% | 34.77% | -167.32% | -1056.88% |
Net Income | -7.17M | -6.16M | -5.54M | -6.78M | -14.41M | -16.43M | -22.09M | -18.91M | -25.54M | -29.07M |
Depreciation & Amortization | 116.45K | 109.44K | 250.56K | 553K | 692K | 777K | 1.51M | 1.9M | 982K | 1.76M |
Stock-Based Compensation | 1.25M | 1.23M | 799.11K | 1.09M | 2.08M | 0 | 6.08M | 6.91M | 8.18M | 6.27M |
Deferred Taxes | -24.18K | -64.32K | 0 | -896K | 202K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 928.39K | 640.03K | 729.29K | 893K | 425K | 3.78M | 2.18M | -245K | 2.27M | 4.74M |
Working Capital Changes | -1.09M | -383.65K | 911.32K | -2.67M | -1.68M | -4.29M | -1.4M | 1.4M | -9.81M | -9.43M |
Change in Receivables | -83.47K | -284.48K | 143.98K | -791K | 627K | -211K | -1.8M | -1.21M | -268K | -3.13M |
Change in Inventory | -469.92K | 122.22K | -1.02M | -25K | -1.71M | -4.42M | 1.25M | 743K | -103K | -306K |
Change in Payables | -512.36M | -316.18K | 928.16K | -453K | -762K | 1.59M | 0 | 3.1M | -7.52M | -5.77M |
Cash from Investing | -26.75K | -63.49K | -160.19K | -482K | -168K | -10.74M | 8.95M | -275K | 615K | 153K |
Capital Expenditures | -26.75K | -63.49K | -160.19K | -482K | -168K | -1.15M | -717K | -275K | -522K | -984K |
CapEx % of Revenue | 0.36% | 0.86% | 1.43% | 3.76% | 1.03% | 5.58% | 2.99% | 0.88% | 1.41% | 2.42% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.14M | 1.14M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 9.67M | 0 | 0 | 0 |
Cash from Financing | 11.99M | -1.49M | 5.6M | 22.69M | 46.88M | 409K | 296K | 6.19M | 50.18M | 49.7M |
Debt Issued (Net) | 0 | -2M | -2.14M | 22.32M | 0 | 0 | 0 | -10M | 48.09M | 19.43M |
Equity Issued (Net) | 11.99M | 0 | 7.43M | 376K | 46.78M | 745K | -210K | 16.15M | 3.95M | 4.15M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -210K | 0 | 0 | 0 |
Other Financing | 0 | 505.38K | 313.29K | 1K | 90K | -336K | 506K | 40K | -1.86M | 26.11M |
Net Change in Cash | 5.97M▲ 0% | -6.19M▼ 203.6% | 2.59M▲ 141.9% | 14.4M▲ 455.1% | 34.01M▲ 136.1% | -26.49M▼ 177.9% | -4.47M▲ 83.1% | -3.04M▲ 32.2% | 26.87M▲ 985.0% | 24.26M▲ 0% |
Free Cash Flow | -6.02M▲ 0% | -4.69M▲ 22.0% | -3.01M▲ 35.9% | -8.29M▼ 175.4% | -12.87M▼ 55.2% | -16.42M▼ 27.6% | -14.44M▲ 12.1% | -9.22M▲ 36.1% | -24.45M▼ 165.0% | -26.7M▲ 0% |
FCF Margin % | -81.57% | -63.84% | -26.83% | -64.62% | -78.93% | -79.9% | -60.27% | -29.39% | -66.12% | -65.75% |
FCF Growth % | -1.66% | 22.02% | 35.88% | -175.44% | -55.19% | -27.63% | 12.08% | 36.1% | -165.01% | -127.46% |
FCF per Share | -0.78 | -0.43 | -0.23 | -0.52 | -0.62 | -0.68 | -0.59 | -0.34 | -0.86 | -0.90 |
FCF Conversion (FCF/Net Income) | 0.84x | 0.75x | 0.51x | 1.15x | 0.88x | 0.98x | 0.62x | 0.47x | 0.94x | 0.92x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 743K | 480K | 0 | 490K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 62K | 0 | 69K |
CLPT Key Ratios
ClearPoint Neuro, Inc. (CLPT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -282.59% | -167.95% | -181.73% | -194.8% | -56.33% | -38.37% | -76.09% | -81.24% | -95.64% | -140.96% |
Return on Invested Capital (ROIC) | -506.35% | -235.15% | -212.39% | -120.36% | -150.16% | -86.81% | -101.31% | -142.21% | -73.7% | -69.55% |
Gross Margin | 60.72% | 66.91% | 64.86% | 71.09% | 68.24% | 65.84% | 56.83% | 60.92% | 61.38% | 61.82% |
Net Margin | -97.12% | -83.82% | -49.39% | -52.86% | -88.41% | -79.97% | -92.21% | -60.25% | -69.08% | -71.57% |
Debt / Equity | 0.84x | 2.30x | 0.54x | 10.15x | 0.25x | 0.32x | 0.66x | 0.14x | 2.08x | 3.37x |
Interest Coverage | -7.21x | -5.29x | -4.80x | -3.70x | -13.81x | -201.90x | - | - | -10.12x | -9.82x |
FCF Conversion | 0.84x | 0.75x | 0.51x | 1.15x | 0.88x | 0.98x | 0.62x | 0.47x | 0.94x | 0.92x |
Revenue Growth | 28.35% | -0.36% | 52.54% | 14.37% | 27.05% | 26.09% | 16.56% | 31.04% | 17.78% | 25.99% |
Related:CLPT Dividend History·CLPT Revenue History·CLPT Price History·CLPT P/E History·CLPT Financial Ratios·CLPT Institutional Holders
CLPT SEC Filings & Documents
ClearPoint Neuro, Inc. (CLPT) SEC filings — annual & quarterly reports (10-K, 10-Q)
CLPT Frequently Asked Questions
ClearPoint Neuro, Inc. (CLPT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ClearPoint Neuro, Inc. (CLPT) reported $40.6M in revenue for fiscal year 2025. This represents a 964% increase from $3.8M in 2011.
ClearPoint Neuro, Inc. (CLPT) grew revenue by 17.8% over the past year. This is strong growth.
ClearPoint Neuro, Inc. (CLPT) reported a net loss of $29.1M for fiscal year 2025.
Dividend & Returns
ClearPoint Neuro, Inc. (CLPT) has a return on equity (ROE) of -95.6%. Negative ROE indicates the company is unprofitable.
ClearPoint Neuro, Inc. (CLPT) had negative free cash flow of $26.7M in fiscal year 2025, likely due to heavy capital investments.